Aptus Pharma Ltd

Aptus Pharma Limited's Board of Directors has approved a proposal to raise up to ₹51 crore for business expansion. The fundraising will be a combination of a preferential allotment of securities up to ₹35 crore, debt finance up to ₹10 crore, and internal accruals of ₹6 crore. The preferential allotment is subject to necessary approvals, including shareholder and regulatory clearances. The Board has delegated authority to the Managing Director to identify and negotiate with prospective investors for the preferential allotment, with final approvals to be sought in subsequent meetings.

Aptus Pharma Ltd has announced a Board Meeting scheduled for June 12, 2026, to consider proposals for raising funds through preferential allotment of equity shares and borrowings. The trading window for designated persons and their immediate relatives will be closed from June 9, 2026, 5:00 PM, until 48 hours after the board meeting outcome is disseminated. The company emphasized that this is an exploratory stage, and specific details of any fund-raising will be disclosed later.

Aptus Pharma Ltd has announced a Board of Directors meeting scheduled for June 12, 2026. The primary agenda items include considering and approving proposals for raising funds through preferential allotment of equity shares and/or other securities, as well as potential borrowings from banks and financial institutions. The Board will also discuss authorizing the Managing Director to engage with potential investors and lenders. Additionally, the company will inform about the closure of the trading window from June 9, 2026, until 48 hours after the board meeting outcome is disseminated, in compliance with SEBI regulations.

Aptus Pharma Ltd has initiated a brand promotion campaign by taking over the Baby Care Room at Rajkot Hirasar Airport. This initiative aims to enhance brand visibility among travelers and families, promoting its upcoming baby care and OTC product portfolio. The company expects this strategic placement to strengthen customer trust, improve market reach, and establish a stronger presence in the OTC and baby care segment.

Aptus Pharma Ltd. disclosed an inter-se transfer of equity shares among the promoter group. Chatrabhujbh Butani sold 101,000 shares off-market on 11.05.2026 and 13.05.2026. Gaurang Rameshchandra Thakker purchased 18,000 shares off-market on 11.05.2026 and 13.05.2026, resulting in a change in their shareholding percentages.

Kripaliben Mayank Thakker acquired 18,000 shares of Aptus Pharma Ltd on May 11, 2026, increasing her stake from 8.38% to 8.64%. This acquisition falls under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The company's equity share capital remains at 68,60,000 shares of ₹10 each after the acquisition.

Kunjal Unadkat increased their shareholding in Aptus Pharma Limited to 8.64% through the acquisition of 18,000 shares on May 11, 2026. This acquisition represents a 0.26% increase in the total share capital. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Riddhish Natwarlal Tanna acquired 18,000 equity shares of Aptus Pharma Limited on May 11, 2026, increasing his stake from 8.38% to 8.64%. The acquisition was an off-market inter-se transfer among the Promoter Group. The company's equity share capital remains at 68,60,000 shares of ₹10 each after the acquisition.

Milly Chetan Lalseta acquired 18,000 equity shares of Aptus Pharma Limited via off-market inter-se transfer among Promoter Group on May 11, 2026, increasing her stake from 8.38% to 8.64%. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The equity share capital of Aptus Pharma Limited remains at 68,60,000 shares of ₹10 each after the acquisition.

Gaurang Thakker has increased his stake in Aptus Pharma Limited to 8.64% through an off-market inter-se transfer among promoters, acquiring 18,000 shares on May 11, 2026. This acquisition falls under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. Before the acquisition, Thakker held 5,75,000 shares (8.38%). Post-acquisition, his holding stands at 5,93,000 shares. The equity share capital of Aptus Pharma remains unchanged at 68,60,000 equity shares of ₹10 each.